Mereo BioPharma (MREO) Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has 5 years of Accumulated Expenses data on file, last reported at $2.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.0 million, down 30.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 30.22% YoY), and the FY2025 annual result was $2.0 million, down 50.23% from the prior year.
• Accumulated Expenses improved to $2.0 million in Q1 2026 per MREO's latest filing, from $2.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $5.5 million in Q4 2023 and troughed at $2.0 million in Q4 2025.
• A 5-year average of $3.7 million and a median of $3.7 million in 2024 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 35.47% in 2025 and fell as far as 50.23% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $5.4 million in 2022, then rose by 0.57% to $5.5 million in 2023, then declined by 25.54% to $4.1 million in 2024, then slumped by 50.23% to $2.0 million in 2025, then advanced by 0.99% to $2.0 million in 2026.
• Business Quant data shows MREO's Accumulated Expenses at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $4.1 million in Q3 2025.